Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Pancreatic Cancer

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510208-39-00

Enrollment

100

Registered

2024-08-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Brief summary

18F-FAPI-74 PET/CT has a 70 % sensitivity in detecting metastatic lymph nodes

Interventions

DRUG[18F]FAPI-74

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
18F-FAPI-74 PET/CT has a 70 % sensitivity in detecting metastatic lymph nodes	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026